Duopharma concludes supply deal for 6.4m doses of Sputnik V vaccine


Duopharma Biotech said the supply of the 6.4 million doses of the Sputnik V vaccine is subject to the approval by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.

KUALA LUMPUR: Duopharma Biotech Bhd has concluded the supply agreements with the Malaysian Government and Russian Direct Investment Fund (RDIF) for the supply of 6.4 million doses of the Sputnik V vaccine.

In a statement on Tuesday, it said the supply of the vaccine is subject to the approval of the vaccine by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Trading ideas: Al-'Aqar REIT, Pantech, AirAsia X, Inta Bina, Khee San, Infoline, Heineken, Agricore
Eupe fourth-quarter profit rises 29%
Meta projects higher spending, weaker revenue
Buyout proposal for Anglo American could reshape copper market
A test bed for airline subscription model
Pantech seeks to list steel pipe units
AI memory boom propels SK Hynix’s numbers
Battery stocks’ rally in India likely to extend
Congo accuses Apple of using ‘blood minerals’ from war-torn east
Higher earnings for Pavilion-REIT

Others Also Read